SUGGESTED FORMULA

_____

Sucrose Effervescent Foam Break-up Tablet (Blank) Human/Vet

Version number: 1.0

Volume: Calibrate Molds Prior to Compound

_____

Sucrose, NF (SU103)	3gm
Citric Acid Anhydrous, USP (CI131)	0.120gm
Sodium Bicarbonate, USP (SO125)	0.100gm
Mannitol, USP (MA165)	3gm
Polyethylene Glycol 3350, USP (PO125)	1gm
Flavor (Dry Form)	Q.S

_____

Wear appropriate personal protective equipment.

SUGGESTED COMPOUNDING PROCEDURES

1. Accurately weigh and/or measure each ingredient
2. Place powders and Triturate until a fine powder mixing well
3. Fill molds with powder mixture and set on sieve or other "holder"
4. Heat molds at 90® for 10 minutes
5. Remove heated molds and place in refrigerator for 10 minutes, then to room temperature for cooling.
6. Un-Mold tablets, package and label
7. Suggested quality assessments:
    a. Weight Variation
    b. Appearance and Disintegration
    c. Label (s)- auxiliary labels (For Oral Use), storage, BUD

*Store in air-tight, light resistance containers and protect from moisture

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available

products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date is estimated to be **6 months** per compounding today

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment. Use safety enclosures (hoods) when weighing and mixing.

4/18 JD